Technical Analysis for ALRN - Aileron Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | 1.08% | |
| Bollinger Band Squeeze | Range Contraction | 1.08% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 6 hours ago |
| 60 Minute Opening Range Breakout | about 10 hours ago |
| Rose Above Lower Bollinger Band | about 10 hours ago |
| Up 2% | about 10 hours ago |
| Up 1% | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/09/2024
Aileron Therapeutics, Inc. Description
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Solid Tumors Tumor Inflammation Molecular Biology Lymphoma Cell Biology Metabolic Disease Oncogenes Peptides Hematological Malignancies Proteins P53 Tumor Suppressor Genes Treatment Of A Range Of Cancer Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.42 |
| 52 Week Low | 1.01 |
| Average Volume | 94,436 |
| 200-Day Moving Average | 3.48 |
| 50-Day Moving Average | 3.64 |
| 20-Day Moving Average | 3.11 |
| 10-Day Moving Average | 3.00 |
| Average True Range | 0.24 |
| RSI (14) | 26.47 |
| ADX | 30.79 |
| +DI | 7.77 |
| -DI | 27.83 |
| Chandelier Exit (Long, 3 ATRs) | 2.72 |
| Chandelier Exit (Short, 3 ATRs) | 3.27 |
| Upper Bollinger Bands | 3.43 |
| Lower Bollinger Band | 2.80 |
| Percent B (%b) | 0.0 |
| BandWidth | 20.09 |
| MACD Line | -0.23 |
| MACD Signal Line | -0.23 |
| MACD Histogram | 0.0022 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.06 | ||||
| Resistance 3 (R3) | 3.04 | 2.94 | 3.01 | ||
| Resistance 2 (R2) | 2.94 | 2.88 | 2.95 | 3.00 | |
| Resistance 1 (R1) | 2.87 | 2.83 | 2.91 | 2.89 | 2.98 |
| Pivot Point | 2.77 | 2.77 | 2.79 | 2.78 | 2.77 |
| Support 1 (S1) | 2.70 | 2.71 | 2.74 | 2.72 | 2.62 |
| Support 2 (S2) | 2.60 | 2.66 | 2.61 | 2.60 | |
| Support 3 (S3) | 2.53 | 2.60 | 2.59 | ||
| Support 4 (S4) | 2.55 |
